ABSTRACT
OBJECTIVE To estab lish a meth od for the determination of 5 volatile components as menthone ，menthol， pulegone，piperitone and ligustilide in Qingxuan pills. METHODS Seven batches of Qingxuan pills were taken as test samples and determined by gas chromatography. The gas chromatographic column was DB- 5 sillica capillary column ，the carrier gas was nitrogen，the inlet temperature was 200 ℃. The sample size was 1 μL，and the split ratio was 10 ∶ 1. The temperature was programmed（the initial temperature was kept at 100 ℃ for 2 min，and then raised to 220 ℃ at 5 ℃/min for 2 min），and the temperature of the flame ionization detector was 250 ℃. RESULTS The chromatographic peaks of menthone ，menthol，pulegone， piperitone and ligustilide reached the baseline separation ；the linear ranges of the five components were 0.008-0.388，0.010-0.527， 0.006-0.327，0.006-0.312，0.053-2.672 mg/mL（all r＞0.999 0）；the average recoveries were 96.33％（RSD＝1.23％，n＝6）， 96.92％（RSD＝1.38％，n＝6），97.53％（RSD＝1.81％，n＝6），96.80％（RSD＝1.89％，n＝6）and 95.61％（RSD＝0.77％， n＝6）；the contents of the five components were 0.009-0.070，0.040-0.157，0.017-0.150，0.008-0.049 and 0.144-0.932 mg/g， respectively. CONCLUSIONS The gas chromatography method established in this study is simple and accurate ，which can simultaneously determine the contents of five volatile components in Qingxuan pills .
ABSTRACT
Objective To investigate the influence of nasal continuous positive airway pressure (nCPAP) therapy on tumor necrosis factor-ot (TNF-α) and interleukin-6 (IL-6) in patients with chronic heart failure (CHF) and severe obstructive sleep apnea syndrome (OSAS).Methods Seventy-two cases with CHF and severe OSAS were divided into treatment group (36 cases) and control group (36 cases) by random digits table.Treatment group was treated by nCPAP and routine drug while control group only by routine drug treatment for 12 weeks.The changes of TNF-α and IL-6 before and after therapy were observed.Results The serum TNF-αt and IL-6 before treatment between two groups was no significant difference (P＞ 0.05).The serum TNF-αt and IL-6 after 12 weeks treatment in both two groups was significantly lower than that before treatment [treatment group:(29.94 ± 8.27) ng/L vs.(13.17 ± 3.61) ng/L,(92.08 ± 11.88) ng/L vs.(46.17 ± 20.01) ng/L;control group:(28.01 ± 7.21) ng/L vs.(22.13 ± 5.43) ng/L,(96.01 ± 12.19) ng/L vs.(68.66 ± 11.10) ng/L] (P ＜ 0.05),the treatment group decreased more significantly (P ＜ 0.05).Conclusion nCPAP therapy could effectively decrease the levels of TNF-α and IL-6 and reduce inflammation response in patients with CHF and severe OSAS.
ABSTRACT
Objective To investigate the clinical efficiency of nasal continuous positive airway pressure (nCPAP) on patients with chronic heart failure(CHF) due to hypertensive heart disease complicated with severe obstructive sleep apnea hypopnea syndrome (OSAHS).Methods Fifty cases with CHF due to hypertensive heart disease complicated with severe OSAHS were divided into treatment group and control group with 25 cases each by the method of random digits table.nCPAP and routine drug treatment were administered in treatment group,while only routine drug treatment was given in control group.Cardiac functional grading,blood pressure,left ventricular end diastolic dimension (LVDd),left ventricular ejection fraction (LVEF),B-type natriuretic peptide (BNP),high-sensitivity C-reactive protein (hs-CRP) were compared before and after 3-month therapy.Results The effective rate in treatment group was significantly higher than that in control group [76.00％(19/25) vs.40.00％(10/25)],and there was significant difference (P ＜0.05).There was significantly decreased in blood pressure in two groups at the end of the therapy [treatment group:(127.52 ± 10.38)/(72.44 ±4.92) mmHg(1 mmHg =0.133 kPa) vs.(176.80 ± 12.90)/ (100.44 ±5.55) mmHg;control group:(150.12 ± 18.96)/ (81.64 ±9.42) mmHg vs.(176.00 ± 11.69)/ (96.08 ± 18.59) mmHg] (P ＜ 0.01),but the blood pressure was significantly lower in treatment group than that in control group (P ＜0.05).LVDd,BNP and hs-CRP in treatment group was declined significantly [(49.12 ± 3.18) mm vs.(57.44 ± 3.62) mm,525.52 ng/L vs.785.25 ng/L,(7.76 ± 1.69) mg/L vs.(18.04 ± 2.58) mg/L](P＜ 0.01);LVEF was significantly increased [(46.12 ± 2.52)％ vs.(38.68 ± 4.65)％](P＜ 0.01).There was no significant difference in LVDd and LVEF in control group before and after therapy (P ＞ 0.05).BNP and hs-CRP also were declined significantly [668.66 ng/L vs.850.96 ng/L,(12.88 ± 2.02) mg/L vs.(19.40 ± 2.30) mg/L] (P ＜ 0.05 or ＜ 0.01),but the above two were significantly lower in treatment group than those in control group(P ＜ 0.05).Conclusion nCPAP therapy can effectively improve the symptoms of heart failure,decrease blood pressure,improve cardiac function,reduce the inflammation response to patients with CHF due to hypertensive heart disease complicated with severe OSAHS.